Secukinumab

Secukinumab is a monoclonal antibody medication that targets interleukin-17A (IL-17A), a protein involved in the inflammatory response. It is used to treat conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis by reducing inflammation and symptoms associated with these autoimmune disorders.

Indications

Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in adult patients who have not responded adequately to conventional therapies.

Dosage

The recommended dosage of secukinumab varies depending on the condition being treated and the patient's weight. Typically, it is administered by subcutaneous injection at specific intervals, as prescribed by a healthcare professional.

Contra-Indications

Secukinumab is contraindicated in patients with a known hypersensitivity to the active substance or any of the excipients in the formulation. It should also be avoided in patients with active infections.

Special Precautions

Before initiating treatment with secukinumab, healthcare providers should assess patients for tuberculosis (TB) infection, as the medication may increase the risk of TB reactivation. Additionally, patients should be monitored for signs of infection during treatment.

Side Effects

Common side effects of secukinumab may include upper respiratory tract infections, headache, diarrhea, and injection site reactions. Serious side effects such as severe infections and allergic reactions are possible but rare.

Drug Interactions

There are no known drug interactions with secukinumab. However, patients should inform their healthcare provider about all medications, including over-the-counter drugs and supplements, before starting treatment.